MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing

Published 11/06/2025, 07:24
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing

ROCKVILLE/LONDON - MaxCyte, Inc. (NASDAQ:MXCT; LSE:MXCT) and Ori Biotech Ltd. announced Wednesday a strategic collaboration to improve efficiency and productivity in cell therapy manufacturing by integrating their respective platforms.

The partnership combines MaxCyte’s ExPERT platform and Flow Electroporation technology with Ori’s IRO manufacturing platform to optimize yield and streamline manufacturing timelines of engineered T cells. The companies will initially evaluate CD19 CAR expression via CRISPR knock-in in activated T cells as their test system.

MaxCyte’s technology provides transfection capabilities at clinical scale, while Ori’s platform offers automated fluid handling, customizable mixing, and tubeless sterile connections. Together, these complementary technologies aim to help therapy developers produce clinically relevant quantities of gene-edited T cells more efficiently.

"We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes," said Maher Masoud, President and CEO of MaxCyte.

Jason C. Foster, CEO of Ori Biotech, added that the partnership demonstrates Ori’s commitment to providing "flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing."

The collaboration seeks to enable developers of advanced therapies to adopt integrated solutions that accelerate the path from research to commercialization of cell therapies.

According to the press release statement, MaxCyte’s technology is currently utilized in over 19 active clinical and commercial programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.